An umbrella review of 54 meta-analyses found that immunonutrition (specialized nutrient formulas containing amino acids, nucleotides, and lipids) was associated with reduced postoperative complications, infections, and hospital stay length in cancer patients undergoing surgery . The effect was most pronounced when given after surgery rather than before.
Malnutrition is a recognized complication in cancer patients, affecting up to 80% of this population depending on cancer type and stage. Poor nutritional status increases surgical risk, compromising immune function and wound healing. Immunonutrition represents a specific category of medical nutrition therapy designed to modulate immune response through targeted nutrient combinations, typically including glutamine, arginine, omega-3 fatty acids, and nucleotides.
Researchers conducted an umbrella review (a systematic review of systematic reviews) across MEDLINE, SCOPUS, and Web of Science databases through September 2025, analyzing 54 meta-analyses that examined immunonutrition interventions in cancer patients undergoing surgery. The analysis pooled data across multiple outcomes measured in randomized controlled trials and observational studies.
The results showed consistent risk reductions across several clinically relevant endpoints. Overall postoperative complications were reduced by 21% (RR = 0.79; 95% CI: 0.70-0.88), with a particularly strong effect on infectious complications, which were reduced by 39% (RR = 0.61; 95% CI: 0.58-0.65). Non-infectious complications showed a more modest 12% reduction (RR = 0.88; 95% CI: 0.82-0.94). Surgical site infections specifically dropped by 34% (RR = 0.66; 95% CI: 0.59-0.74), and anastomotic leak (a serious complication in gastrointestinal surgery) fell by 31% (RR = 0.69; 95% CI: 0.62-0.77). Hospital length of stay was reduced by approximately 1.75 days on average.
A critical finding emerged when researchers stratified the data by timing of intervention. Postoperative immunonutrition appeared more effective than preoperative or perioperative approaches, reducing overall complications by 31% (RR = 0.69; 95% CI: 0.54-0.89) and shortening hospital stay by 2.26 days. This contrasts with preoperative and perioperative timing, which showed smaller benefits. Mortality showed a borderline reduction (HR = 0.86; 95% CI: 0.74-0.99), suggesting possible but not conclusively established benefit for survival outcomes.
The heterogeneity across studies was variable but generally manageable, with some outcomes showing high variation (hospital stay, I2 = 90.3%) while others were quite consistent (anastomotic leak and non-infectious complications, I2 = 0%). This suggests outcome-specific factors influence the magnitude of benefit observed.
If you're facing cancer surgery, the evidence suggests immunonutrition support may meaningfully reduce your risk of postoperative complications and infections. The data is particularly strong for infectious complications and surgical site infections, both of which substantially impact recovery time and outcomes.
The timing insight is practically important: postoperative immunonutrition appears to deliver more benefit than preparation beforehand. This may reflect the shifted metabolic demands immediately after surgery, when immune suppression and tissue damage peak. However, this finding should be interpreted cautiously, as it's a subgroup analysis and not the primary design of the underlying studies.
The approximately 1.75-day reduction in hospital stay, while modest in absolute terms, translates to meaningful reductions in infection exposure risk and healthcare costs. For serious complications like anastomotic leak (which can be life-threatening), a 31% relative reduction represents substantial clinical benefit.
This review does not establish which specific nutrient components drive benefits or what optimal dosing looks like. "Immunonutrition" encompasses multiple formulation approaches. Work with your surgical team and a nutrition specialist to understand whether a specific immunonutrition protocol is appropriate for your cancer type and surgical plan. Standard perioperative nutrition support remains a baseline regardless of these findings.
| Parameter | Details |
|---|---|
| Study Type | Umbrella review of meta-analyses (systematic review of systematic reviews) |
| Studies Analyzed | 54 meta-analyses |
| Population | Cancer patients undergoing surgery |
| Intervention | Immunonutrition formulas (typically containing glutamine, arginine, nucleotides, omega-3 fatty acids) |
| Control | Standard nutrition support or usual care |
| Primary Outcomes | Postoperative complications, infectious complications, surgical site infections, anastomotic leak, mortality, hospital length of stay |
| Databases | MEDLINE/PubMed, SCOPUS, Web of Science |
| Search Period | Inception through September 2025 |
| Journal | BMC Cancer |
| PubMed ID | 42316063 |
Umbrella review on immunonutrition and cancer surgery outcomes: PubMed: 42316063
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.